Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS

NCT04810611 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

33

Enrollment

INDUSTRY

Sponsor class

Stopped Business reasons

Conditions

Myelodysplastic Syndromes

Interventions

DRUG: MBG453
DRUG: NIS793
DRUG: canakinumab

Sponsor

Novartis Pharmaceuticals